Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

The emergence of immune checkpoint inhibitors (ICIs), mainly including anti-programmed
cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) and anti-cytotoxic T …

The KEAP1-NRF2 pathway is the key regulator of cellular defense against both extrinsic and
intrinsic oxidative and electrophilic stimuli. Since its discovery in the 1990s, its seminal role …

Immune checkpoints are inhibitory receptor/ligand pairs regulating immunity that are
exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the …

The expression of inhibitory immune checkpoint molecules, such as programmed death-
ligand (PD-L) 1, is frequently observed in human cancers and can lead to the suppression of …

The gene expression program induced by NRF2 transcription factor plays a critical role in
cell defense responses against a broad variety of cellular stresses, most importantly …

CMTM6, a regulator of PD-L1 expression, also modulates tumor immunity. Little is known
about the function of CMTM6 and its mechanism of action in head and neck squamous cell …

Melanoma is one of the seven most common cancers in the United States, and its incidence
is still increasing. Since 2011, developments in targeted therapies and immunotherapies …

Unlike traditional cancer therapies, such as surgery, radiation and chemotherapy that are
typically non-specific, cancer immunotherapy harnesses the high specificity of a patient's …

With the recent approvals for the application of monoclonal antibodies that target the well-
characterized immune checkpoints, immune therapy shows great potential against both …